Arkolith/Insider Trading/IMMX/Form 4

Morris Gabriel S

CFO, DirectorImmix Biopharma, Inc. (IMMX) · full profile →Form 4 · filed Dec 10, 2025
Net Buying
Open-Market Buys
$5K
Open-Market Sells
$0
Net Open-Market Flow
$5K
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 10, 2025Buy(P)770$6.58$5K291K
Dec 8, 2025Option exercise(X)156K$0.80$125K427K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 8, 2025Option exercise(X)96K—$00
Dec 8, 2025Option exercise(X)60K—$00

Transaction Codes

P
Open-market purchase
X
Exercise of in-the-money derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-25-027107) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML